国投证券股份有限公司、中信证券股份有限公司 关于石药创新制药股份有限公司终止发行股份及支付现金购买资产 并募集配套资金暨关联交易事项相关主体买卖股票情况 的自查报告的核查意见 石药创新制药股份有限公司（以下简称"石药创新"、"公司"或"上市公司"） 拟以发行股份及支付现金方式购买石药集团维生药业（石家庄）有限公司、石药 （上海）有限公司、石药集团恩必普药业有限公司（以下简称"恩必普药业"）合 计持有的石药集团百克（山东）生物制药股份有限公司（以下简称"标的公司"） 100%股权，并募集配套资金（以下简称"本次交易"）。 上市公司于 2025 年 4 月 28 日召开第六届董事会第二十四次会议、第六届监 事会第十九次会议，审议通过了《关于终止发行股份及支付现金购买资产并募集 配套资金暨关联交易事项并撤回申请文件的议案》，同意公司终止发行股份及支 付现金购买资产并募集配套资金暨关联交易事项。 国投证券股份有限公司、中信证券股份有限公司（以下简称"独立财务顾问"） 作为本次交易的独立财务顾问，根据《上市公司重大资产重组管理办法》《公开 发行证券的公司信息披露内容与格式准则第 26 号——上市公司重大资产重组》 《深 ...

Core Viewpoint - The white liquor sector is expected to experience increased differentiation, with companies facing challenges in maintaining performance growth while ensuring healthy distribution channels. The overall financial performance of the sector is anticipated to remain under pressure in 2025, with solid companies likely to achieve stable growth, while weaker companies may continue to decline [1][2]. Group 1: Market Performance - As of May 13, 2025, the CSI Major Consumer Index (000932) rose by 0.05%, with key stocks such as Proya (603605) increasing by 2.69% and XinNuoWei (300765) by 1.96% [1]. - The Major Consumer ETF (159672) increased by 0.13%, with a latest price of 0.78 yuan and a turnover rate of 4% during the trading session, amounting to 3.36 million yuan [1]. - Over the past year, the average daily trading volume of the Major Consumer ETF was 5.69 million yuan [1]. Group 2: White Liquor Sector Insights - The white liquor industry is expected to show resilience over the long term, benefiting from economic recovery and increased consumption due to stimulus policies [2]. - The differentiation within the white liquor sector is projected to intensify, with companies needing to navigate performance challenges while maintaining healthy distribution channels [1][2]. Group 3: ETF Performance Metrics - The Major Consumer ETF has seen a significant growth of 1.56 million yuan in scale over the past two weeks, ranking in the top fifth among comparable funds [2]. - Since its inception, the Major Consumer ETF has recorded a highest single-month return of 24.35% and an average monthly return of 5.36% [2]. - As of May 12, 2025, the ETF's maximum drawdown this year was 5.57%, with a relative benchmark drawdown of 0.34% [3]. Group 4: Fee Structure and Tracking Accuracy - The management fee for the Major Consumer ETF is 0.50%, and the custody fee is 0.10%, which are among the lowest in comparable funds [4]. - The tracking error for the Major Consumer ETF over the past month was 0.014%, indicating the highest tracking precision among comparable funds [5]. Group 5: Valuation and Top Holdings - The latest price-to-earnings ratio (PE-TTM) for the CSI Major Consumer Index is 20.15, which is at a historical low, being below 89.64% of the time over the past year [5]. - As of April 30, 2025, the top ten weighted stocks in the CSI Major Consumer Index accounted for 67.16% of the index, including major players like Yili (600887) and Kweichow Moutai (600519) [5].

简历显示：赵伟先生:中国,硕士研究生。历任葛兰素史克(上海)医药研发有限公司药物化学部助理研究 员、广发证券股份有限公司投资自营部医药研究员、招商基金管理有限公司研究部医药组组长及招商基 金管理有限公司国际业务部基金经理助理。现任农银汇理基金管理有限公司基金经理。2019年11月8日 至2021年3月5日担任农银汇理中小盘混合型证券投资基金基金经理。2020年1月13日至2021年3月5日担 任农银汇理行业成长混合型证券投资基金基金经理。2020年1月21日至2021年3月5日任职农银汇理创新 医疗混合型证券投资基金基金经理。2017年6月20日至2021年3月5日担任农银汇理医疗保健主题股票型 证券投资基金基金经理。曾任农银汇理中国优势灵活配置混合型证券投资基金基金经理。2021年03月加 入富国基金管理有限公司,2021年7月6日起担任富国精准医疗灵活配置混合型证券投资基金基金经理。 2024年04月23日起担任富国科创板两年定期开放混合型证券投资基金基金经理。 金融界2025年5月12日消息，富国精准医疗混合A(005176) 最新净值2.6542元，下跌3.50%。该基金近1个 月收益率-2.01%， ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive returns in recent months and has a diversified portfolio in the healthcare sector [1][3] - As of May 9, 2025, the latest net value of the fund is 2.5040 yuan, with a growth of 0.72%. The fund's return over the past month is 5.17%, ranking 504 out of 783 in its category; over the past three months, the return is 9.06%, ranking 88 out of 778; and year-to-date, the return is 9.87%, ranking 103 out of 773 [1] - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Mindray Medical (2.80%) [1] Group 2 - The fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan. The fund managers are Zhao Bei and Ding Yang [1] - Zhao Bei has extensive experience in the healthcare sector, having served as the fund manager for various healthcare-related funds since 2014, while Ding Yang joined the company in 2017 and currently serves as a fund manager [2]

证券代码：300765 证券简称：新诺威 公告编号：2025-047 石药创新制药股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）于 2025 年 3 月 19 日召开第 六届董事会第二十二次会议、第六届监事会第十七次会议，于 2025 年 4 月 15 日 召开 2024 年年度股东大会，会议审议并通过了《关于使用部分闲置募集资金及 自有资金进行现金管理的议案》。在不影响募集资金投资项目建设和公司正常经 营的情况下，公司及子公司使用不超过人民币 8.00 亿元（含本数）额度的闲置募 集资金及不超过人民币 8.00 亿元（含本数）的自有资金进行现金管理，投资安全 性高、流动性好的保本型产品（包括结构性存款、大额存单等），使用期限自股 东大会审议通过之日起 12 个月内有效。在上述额度及决议有效期内，业务可循 环滚动开展。具体内容详见巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于使用部分闲置募集资金及自有资金进行现金管理的公告》 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-046 石药创新制药股份有限公司 关于控股股东增持公司股份计划实施完成的公告 控股股东石药集团恩必普药业有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 1、石药创新制药股份有限公司（以下简称"公司"）于 2024 年 11 月 8 日 披露《关于控股股东增持公司股份计划的公告》（公告编号：2024-102），公司 控股股东石药集团恩必普药业有限公司（以下简称"恩必普药业"）计划自 2024 年 11 月 8 日（含本日）起 6 个月内，择机增持公司股份，增持金额不低于人民 币 10,000.00 万元，不超过人民币 12,000.00 万元。 2、增持计划的进展情况：截至本公告披露日，恩必普药业的增持计划已实 施完成。自 2024 年 11 月 8 日至 2025 年 5 月 7 日，恩必普药业通过深圳证券交 易所交易系统以集中竞价方式累计增持公司股份 3,313,900 股，占公司总股本的 0.24%（已剔除最新披露的公司 ...

关于 石药创新制药股份有限公司 控股股东增持公司股份 之 法律意见书 中国北京东城区金宝街 89 号金宝大厦 11 层 邮编：100005 11F, Jinbao Tower, 89 Jinbao Street, Dongcheng District, Beijing 100005, P.R.C. 电话(Tel)： (86-10) 6652 3388 传真(Fax)：（86-10）6652 3399 网址（Website）： www.junzejun.com 电子信箱（E-mail）：jzj@junzejun.com 释 义 在本法律意见书中，除非文义另有所指，下列左栏中的术语或简称对应右栏 中的含义或全称： | 公司、新诺威 | 指 | 石药创新制药股份有限公司 | | --- | --- | --- | | 增持人、控股股东、恩必 | 指 | 石药集团恩必普药业有限公司，现为公司控股股东 | | 普药业 | | | | 本次增持 | 指 | 恩必普药业拟自 2024 年 11 月 8 日（含本日）起 6 个月内， 万元， | | | | 择机增持公司股份，增持金额不低于人民币 10,000.00 | | ...

Core Viewpoint - New Nuo Wei (300765.SZ) announced the termination of its application for the acquisition of Shiyao Chuangxin Pharmaceutical Co., Ltd. and the associated fundraising, ending a 15-month effort for a significant restructuring deal worth 7.6 billion yuan [2][3]. Group 1: Termination of Acquisition - The termination was due to changes in the pharmaceutical industry and capital market environment since the initial planning of the restructuring, leading to a decision made in the interest of long-term shareholder benefits [2][3]. - The market reacted rationally to the termination, influenced by factors such as stock price fluctuations, increasing performance burdens, and declining acquisition targets [2][3]. Group 2: Financial Performance and Challenges - New Nuo Wei's revenue and profit have been declining, with a 21.98% year-on-year decrease in revenue to 1.981 billion yuan and an 87.63% drop in net profit to 54 million yuan in 2024 [8]. - The company's core revenue from functional foods and raw materials fell by 24.90% to 1.84 billion yuan, while the biopharmaceutical sector contributed only 87.8 million yuan, despite a 153.0% increase [10]. Group 3: Acquisition Details and Valuation - The acquisition target, Shiyao Baike, has a core product, Jinyouli, which is facing growth challenges, with a significant reliance on a single product and limited growth potential [4][7]. - The valuation for Shiyao Baike was set at 7.622 billion yuan, representing a 78.25% premium over its book value of 4.276 billion yuan, raising concerns about the high price for low-growth assets [6][7]. Group 4: R&D and Future Prospects - New Nuo Wei's R&D expenses increased by 25.44% to 842 million yuan in 2024, primarily due to the inclusion of Shiji Biological's R&D costs, indicating a significant financial burden [10][11]. - The company is under pressure from negative cash flows, with net cash flow from operating activities at -1.235 billion yuan in 2024 and -87 million yuan in the first quarter of 2025 [12][13].

Core Viewpoint - New Nuo Wei (300765.SZ) has terminated its acquisition of Shiyao Baike, with the Shenzhen Stock Exchange halting the review of the asset purchase and fundraising application due to changes in the pharmaceutical industry and capital market conditions since the initial planning of the restructuring [1][3]. Group 1: Acquisition Details - The acquisition was initially approved by New Nuo Wei's board in January 2024, intending to purchase 100% of Shiyao Baike for a total consideration of 7.6 billion yuan, with 90% paid in shares and 10% in cash [2][3]. - The transaction was expected to enhance New Nuo Wei's biopharmaceutical portfolio, particularly in long-acting proteins and innovative drug pipelines [2][3]. Group 2: Financial Performance - New Nuo Wei has experienced a decline in revenue and net profit for two consecutive years, with revenues of 25.39 billion yuan in 2023 and 19.81 billion yuan in 2024, representing year-on-year decreases of 4.75% and 21.98%, respectively [6]. - The net profit for 2023 and 2024 was reported at 4.34 billion yuan and 537.26 million yuan, showing declines of 40.18% and 87.63% year-on-year [6]. - In Q1 2025, New Nuo Wei reported revenues of 472 million yuan, a 9.94% decrease year-on-year, and a net loss of 26.90 million yuan compared to a profit of 79.06 million yuan in the same period the previous year [8]. Group 3: R&D and Market Conditions - The company has significantly increased its R&D expenditures, reaching 840 million yuan in 2024, a 25.44% increase from the previous year, with Q1 2025 R&D expenses at 240 million yuan, up 117.68% year-on-year [6][9]. - New Nuo Wei's strategic focus includes ADCs, mRNA vaccines, and antibody drugs, with over 20 products in the pipeline and several achieving important milestones in 2024 [7].

Core Insights - The latest net value of ICBC Frontier Medical Stock A (001717) is 2.8300 yuan, reflecting a decrease of 1.77% [1] - The fund has shown a one-month return of 5.28%, ranking 400 out of 471 in its category; a three-month return of 8.06%, ranking 71 out of 471; and a year-to-date return of 7.56%, ranking 113 out of 469 [1] Fund Holdings - The top ten holdings of ICBC Frontier Medical Stock A account for a total of 59.05%, with the largest positions being: - Heng Rui Medicine (10.11%) - Kelun Pharmaceutical (8.01%) - WuXi AppTec (7.72%) - BeiGene (6.85%) - Xinlitai (4.90%) - Zai Lab (4.77%) - Yuyue Medical (4.60%) - New Horizon Health (4.36%) - East China Pharmaceutical (4.20%) - Haizhi Pharmaceutical (3.53%) [1] Fund Overview - ICBC Frontier Medical Stock A was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2]